Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes

Karam Kostner; Stephen Nicholls; John Amerena; Alex Brown; Mark Cooper; Chris Hammett; Richard O'Brien; Leonard Kritharides; David L. Hare; Gerald F. Watts; Philip Aylward

doi:10.1016/j.hlc.2016.09.005

Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes

Karam Kostner, Stephen Nicholls, John Amerena, Alex Brown, Mark Cooper, Chris Hammett, Richard O'Brien, Leonard Kritharides, David L. Hare, Gerald F. Watts, Philip Aylward

College of Medicine and Public Health

Research output: Contribution to journal › Editorial

1 Citation (Scopus)

Abstract

There is overwhelming evidence that intensive statin therapy reduces atherogenic lipoproteins as well as cardiovascular events post acute coronary syndromes (ACS) [1], [2]. Furthermore, post-hoc analyses from randomised trials show that the benefit of statin therapy depends on the extent of LDL reduction [3]; patients achieving very low LDL cholesterol (LDL-C) levels in statin trials are at very low cardiovascular (CV) risk [4] and show no increased risk of adverse events related to the achievement of very low LDL-C levels.

Original language	English
Pages (from-to)	1051-1054
Number of pages	4
Journal	Heart, Lung and Circulation
Volume	25
Issue number	11
DOIs	https://doi.org/10.1016/j.hlc.2016.09.005
Publication status	Published - 1 Nov 2016

Keywords

Coronary Syndromes
intensive LDL reduction
improved outcomes
post acute

Access to Document

10.1016/j.hlc.2016.09.005Licence: In Copyright

Cite this

@article{efee2a1af9484c00a6a690b93552c1be,

title = "Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes",

abstract = "There is overwhelming evidence that intensive statin therapy reduces atherogenic lipoproteins as well as cardiovascular events post acute coronary syndromes (ACS) [1], [2]. Furthermore, post-hoc analyses from randomised trials show that the benefit of statin therapy depends on the extent of LDL reduction [3]; patients achieving very low LDL cholesterol (LDL-C) levels in statin trials are at very low cardiovascular (CV) risk [4] and show no increased risk of adverse events related to the achievement of very low LDL-C levels.",

keywords = "Coronary Syndromes, intensive LDL reduction, improved outcomes, post acute",

author = "Karam Kostner and Stephen Nicholls and John Amerena and Alex Brown and Mark Cooper and Chris Hammett and Richard O'Brien and Leonard Kritharides and Hare, {David L.} and Watts, {Gerald F.} and Philip Aylward",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.hlc.2016.09.005",

language = "English",

volume = "25",

pages = "1051--1054",

journal = "Heart, Lung and Circulation",

issn = "1443-9506",

publisher = "Elsevier Australia",

number = "11",

}

TY - JOUR

T1 - Intensive LDL Reduction Post Acute Coronary Syndromes

T2 - A Catalyst for Improved Outcomes

AU - Kostner, Karam

AU - Nicholls, Stephen

AU - Amerena, John

AU - Brown, Alex

AU - Cooper, Mark

AU - Hammett, Chris

AU - O'Brien, Richard

AU - Kritharides, Leonard

AU - Hare, David L.

AU - Watts, Gerald F.

AU - Aylward, Philip

PY - 2016/11/1

Y1 - 2016/11/1

N2 - There is overwhelming evidence that intensive statin therapy reduces atherogenic lipoproteins as well as cardiovascular events post acute coronary syndromes (ACS) [1], [2]. Furthermore, post-hoc analyses from randomised trials show that the benefit of statin therapy depends on the extent of LDL reduction [3]; patients achieving very low LDL cholesterol (LDL-C) levels in statin trials are at very low cardiovascular (CV) risk [4] and show no increased risk of adverse events related to the achievement of very low LDL-C levels.

AB - There is overwhelming evidence that intensive statin therapy reduces atherogenic lipoproteins as well as cardiovascular events post acute coronary syndromes (ACS) [1], [2]. Furthermore, post-hoc analyses from randomised trials show that the benefit of statin therapy depends on the extent of LDL reduction [3]; patients achieving very low LDL cholesterol (LDL-C) levels in statin trials are at very low cardiovascular (CV) risk [4] and show no increased risk of adverse events related to the achievement of very low LDL-C levels.

KW - Coronary Syndromes

KW - intensive LDL reduction

KW - improved outcomes

KW - post acute

UR - http://www.scopus.com/inward/record.url?scp=84991710750&partnerID=8YFLogxK

U2 - 10.1016/j.hlc.2016.09.005

DO - 10.1016/j.hlc.2016.09.005

M3 - Editorial

C2 - 27725093

AN - SCOPUS:84991710750

SN - 1443-9506

VL - 25

SP - 1051

EP - 1054

JO - Heart, Lung and Circulation

JF - Heart, Lung and Circulation

IS - 11

ER -

Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this